Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KuicK Research | PRODUCT CODE: 1496174

Cover Image

PUBLISHER: KuicK Research | PRODUCT CODE: 1496174

Global KRAS Inhibitors Market & Clinical Trials Future Outlook 2030

PUBLISHED:
PAGES: 250 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 2400
PDF (Multi-User License)
USD 4800

Add to Cart

Global KRAS Inhibitors Market & Clinical Trials Future Outlook 2030 Report Highlights:

  • Global KRAS Inhibitors Sales Growth In 2023: 10%
  • Global KRAS Inhibitors Market Opportunity: > 600 Million By 2030
  • Global KRAS Inhibitor Market Insight By Region & Indications
  • Approved KRAS Inhibitors: 2
  • KRAS Inhibitors In Clinical Trials > 90 Drugs
  • Global KRAS Inhibitor Clinical Trials Insight By Country, Company, Indication & Phase

With the ubiquitous prevalence of cancer ailments oscillating year by year, the sophisticated treatment approaches are vastly sought subsequently. With this respect, the market in conjugation with forecast for the domain of global KRAS inhibitor sector emerges as a newfangled mainstay for shareholders as well as researchers in the medical and biotechnological panorama. Currently, the market for this segment is dominated by the US due to the region's strong drug sales, augmenting approval of KRAS inhibitors by the US government and presence of different funding agencies; however, other region, like China, is also an emerging area as evident from preclinical and clinical studies. As the realm of KRAS inhibitor encircles trailblazing advancements along with evolution; a noteworthy industry emphasis in KRAS inhibitor sphere, with opportunities of considerable progress, is expected in the imminent years.

Hitherto, the global industry of KRAS inhibitor has acknowledged an incredible growth, fueled by the remarkable growth in research and development, clinical triumph in commercial sector in addition to the transformative potential of this innovative treatment modality. The first KRAS inhibitor, Lumakras (sotorasib), developed by Amgen in May 2021, and subsequent approval of inhibitor of the RAS GTPase family, Krazati (adagrasib), developed by Mirati Therapeutics, a wholly owned subsidiary of Bristol Myers Squibb, is second commercially accessible KRAS inhibitor, marking a chronicle breakthrough in the field of cancer care.

It is clearly evident that the commercial market of KRAS inhibitor is witnessing boom in the recent years on the account of several market dynamics. Aspects such as rise in preclinical and clinical trials, involvement of stakeholders, and technological advancement coupled with increase in healthcare expenditure are fueling the market growth of KRAS inhibitors. For instance, Zhejiang Cancer Hospital in collaboration with Suzhou Genhouse Bio plans to begin a multi-center, open-label phase Ib/II study in order to evaluate the safety, tolerability, pharmacokinetics, and efficacy of GH21 combined with D-1553 in patients with advanced or metastatic solid tumors harboring KRAS G12C mutation in July 2024.

The up-to-date global market trend of combination therapies has gained limelight in the recent years in which the notion of using combination of KRAS inhibitors with other therapeutic approaches is experimental. Data from preliminary studies have revealed that amalgamation therapies contain diverse drugs that target different proteins in order to empower the blockade of different pathways at once. Henceforth, many combination studies of KRAS inhibitors with immune checkpoint inhibitors, antibodies, cancer vaccines, chemotherapy, targeted therapies and many more are ongoing in the KRAS inhibitor realm. Such as, a phase 3 trial, CodeBreaK 200, is evaluating sotorasib in combination with chemotherapy (docetaxel or pemetrexed/platinum) in advanced non-small cell lung cancer patients with KRAS G12C mutations is one example, representing novel avenue.

Above and beyond, it is foreseeable that a handful of more KRAS inhibitors are anticipated to be launched in the approaching years as many innovative KRAS inhibitors have received priority designations in the recent years. For instance, in February 2024, FDA has acknowledged priority review the supplemental new drug application (sNDA) for Krazati (adagrasib) in combination with cetuximab for the management of patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) and the FDA allocated a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024.

As a final point, the segment of KRAS inhibitors is vastly promising that clenches plausibility to alter treatment landscape of cancer diseases. Apart from that, KRAS inhibitors can additionally be utilized to treat other diseases, besides cancer, including inflammatory, eye disorders etc. Moreover, the presences of pharma companies, comprising Revolution Medicine, Erasca, Jacobio Pharma Gr Co, Quanta Therapeutics along with giant pharma like Bristol Myers Squibb, AstraZeneca, Roche, Merck, Incyte Corporation, Sanofi, etc. further aid to expand the KRAS inhibitor arena by conducting enormous preclinical and clinical studies. Overall, the future for KRAS inhibitors looks optimistic, offering beacon of anticipation to patients.

Table of Contents

1. Introduction to KRAS Inhibitors

  • 1.1 Development of KRAS Inhibitors
  • 1.2 Mechanism Of Action
  • 1.3 Role of KRAS Inhibitors in Cancer Therapy

2. Lumakras - First Approved KRAS Inhibitor

  • 2.1 Overview & Patent Insight
  • 2.2 Dosage & Price Analysis
  • 2.3 Sales Analysis

3. Krazati - Second Approved KRAS Inhibitor

  • 3.1 Overview & Patent Insight
  • 3.2 Dosage & Price Analysis
  • 3.3 Sales Analysis

4. Global KRAS Inhibitor Market Outlook

  • 4.1 Current Market Scenario
  • 4.2 KRAS Inhibitors Candidates Granted Breakthrough & Orphan Designations
  • 4.3 Future Market Opportunity

5. KRAS Inhibitor Market Regional Analysis: Commercial & Clinical Development Outlook

  • 5.1 US
  • 5.2 UK
  • 5.3 China
  • 5.4 Europe
  • 5.5 Japan
  • 5.6 South Korea
  • 5.7 Canada
  • 5.8 Taiwan
  • 5.9 Australia

6. KRAS Inhibitor Market By Indications: Clinical Trials & Modernization Insights

  • 6.1 Lung Cancer
  • 6.2 Colorectal Cancer
  • 6.3 Pancreatic Cancer
  • 6.4 Other Indications

7. Global KRAS Inhibitors Clinical Pipeline Overview

  • 7.1 By Country
  • 7.2 By Phase
  • 7.3 By Company
  • 7.4 By Indication
  • 7.5 By Patient Segment

8. Global KRAS Inhibitor Clinical Trials Insight By Country, Company, Indication & Phase

  • 8.1 Research
  • 8.2 Preclinical
  • 8.3 Phase I
  • 8.4 Phase I/II
  • 8.5 Phase II
  • 8.6 Phase II/III
  • 8.7 Phase III
  • 8.8 Preregistration

9. Marketed KRAS Inhibitor Clinical Trials Insight By Country, Company & Indication

10. Combination Strategies with KRAS Inhibitors

  • 10.1 Immunotherapy
  • 10.2 Oncolytic Virus Immunotherapy
  • 10.3 Chemotherapy
  • 10.4 Targeted Therapies

11. Global KRAS Inhibitors Market Dynamics

  • 11.1 Market Drivers
  • 11.2 Market Challenges

12. Competitive Landscape

  • 12.1 Array BioPharma (Pfizer)
  • 12.2 Applied Pharmaceutical Science
  • 12.3 Amgen
  • 12.4 AnBogen Therapeutics
  • 12.5 Ascentage Pharma
  • 12.6 AstraZeneca
  • 12.7 Biond Biologics
  • 12.8 BridgeBio Pharma
  • 12.9 Bristol Myers Squibb
  • 12.10 Boehringer Ingelheim
  • 12.11 Carmot Therapeutics (Roche)
  • 12.12 Eli Lilly
  • 12.13 Erasca
  • 12.14 FogPharma
  • 12.15 Frontier Medicines
  • 12.16 Jacobio Pharmaceuticals
  • 12.17 Jemincare
  • 12.18 Jiangsu Hansoh Pharmaceutical
  • 12.19 Jiangsu Hengrui Medicine Co.
  • 12.20 Loxo Oncology (Eli Lilly)
  • 12.21 Mirati Therapeutics
  • 12.22 Quanta Therapeutics
  • 12.23 REVOLUTION Medicines
  • 12.24 Roche
  • 12.25 Suzhou Genhouse Bio
  • 12.26 Suzhou Zelgen Biopharmaceuticals

List of Tables

Table 2 1: Recommended Lumakras Dosage Modifications for Adverse Reactions

Table 3 1: Recommended Krazati Dosage Modifications for Adverse Reactions

Table 4 1 KRAS inhibitors Granted Designations

  • Table 5-1: UK - Ongoing Clinical Trials for KRAS Inhibitors
  • Table 5-2: China - Some KRAS inhibitors in Ongoing Clinical trials
  • Table 5-3: Japan -Ongoing Clinical Trials for KRAS inhibitor as Monotherapy
  • Table 5-4: Japan -Ongoing Clinical Trials for KRAS inhibitor as Combination Therapies
  • Table 5-5: South Korea - Ongoing Clinical Trials for KRAS Inhibitors
  • Table 5-6: Canada - Ongoing Clinical Trials for KRAS Inhibitors
  • Table 5-7: Taiwan - Ongoing Clinical Trials for KRAS Inhibitors
  • Table 5-8: Australia - Ongoing Clinical Trials for KRAS Inhibitors
  • Table 6-1: Colorectal Cancer - KRAS Inhibitors in Clinical Trials
  • Table 6-2: Colorectal Cancer - KRAS Inhibitors with Regulatory Designations
  • Table 6-3: Pancreatic Cancer - KRAS Inhibitors in Clinical Trials
  • Table 6-4: Pancreatic Cancer - KRAS Inhibitors with Regulatory Designations

List of Figures

  • Figure 1-1: RAS Mutation - Frequency of KRAS Mutation v/s HRAS & NRAS Mutations
  • Figure 1-2: Historical Development of KRAS Inhibitors
  • Figure 1-3: General Mechanism of KRAS Inhibitors against Cancer
  • Figure 1-4: Targeting Approaches of KRAS Inhibitors
  • Figure 1-5: Direct Targeting of Mutant KRAS
  • Figure 1-6: Targets for Modifying the KRAS Membrane Association
  • Figure 1-7: KRAS Mutational Frequency by Organs (%)
  • Figure 1-8: Roles of KRAS Inhibitors in Cancer Treatment
  • Figure 2-1: Lumakras - Approval Year By Region
  • Figure 2-2: US - Lumakras Patent Expiration Year
  • Figure 2-3: Europe - Lumakras Patent Expiration Year
  • Figure 2-4: Lumakras - Cost per Tablet & Supply of 120mg (US$), June'2024
  • Figure 2-5: Lumakras - Cost per Tablet & Supply of 320mg (US$), June'2024
  • Figure 2-6: Lumakras - Cost per Tablet & Supply of 120mg (EUR & US$), June'2024
  • Figure 2-7: Lumakras - Recommended Dose Reduction Level for Adverse Reaction
  • Figure 2-8: Global - Lumakras/Lumykras Annual Sales (US$ Million), 2021-2024*
  • Figure 2-9: Global - Lumakras/Lumykras Quarterly Sales (US$ Million), 2024
  • Figure 2-10: Global - Lumakras/Lumykras Sales by Region (US$ Million), 2023
  • Figure 2-11: Global - Lumakras/Lumykras Annual Sales by Region (%), 2023
  • Figure 2-12: Global - Lumakras/Lumykras Quarterly Sales (US$ Million), 2023
  • Figure 2-13: US - Lumakras/Lumykras Quarterly Sales (US$ Million), 2023
  • Figure 2-14: ROW - Lumakras/Lumykras Quarterly Sales (US$ Million), 2023
  • Figure 3-1: Krazati - Approval Year By Region
  • Figure 3-2: Krazati - Cost per Tablet & Supply of 200mg (US$), June'2024
  • Figure 3-3: Krazati - Recommended Dosage Reduction for Adverse Reactions
  • Figure 3-4: US - Krazati Annual Sales (US$ Million), 2024
  • Figure 4-1: Global - KRAS Inhibitors Sales (US$ Million), 2021-2024*
  • Figure 4-2: KRAS Inhibitors - Future Market Opportunities
  • Figure 4-3: Global - KRAS Inhibitors Sales (US$ Million), 2024-2030
  • Figure 5-1: Quanta Therapeutics - KRAS Inhibitors IND Clearance & Submission Status
  • Figure 5-2: QTX3034 with Cetuximab Phase I (NCT06227377) Study - Initiation & Completion Year
  • Figure 5-3: Krazati with Cetuximab Granted FDA Priority Review & PFUDA Date of June'24
  • Figure 5-4: MK-1084 With Pembrolizumab Phase III (NCT06345729) Study - Initiation & Completion Year
  • Figure 5-5: Verastem Oncology KRAS Combiantional Study
  • Figure 5-6: KRAS Vaccine Combined with Balstilimab & Botensilimab Phase I (NCT06411691) Study - Initiation & Completion Year
  • Figure 5-7: BBO-8520 with Pembrolizumab Phase I (NCT06343402) Study - Initiation & Completion Year
  • Figure 5-8: INCB161734 Phase I (NCT06179160) Study - Initiation & Completion Year
  • Figure 5-9: Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib Phase I/II (NCT05074810) Study - Initiation & Completion Year
  • Figure 5-10: Jazz Pharmaceutical & Redx Pharma Collaboration
  • Figure 5-11: BI 3706674 Phase I (NCT06056024) Study - Initiation & Completion Year
  • Figure 5-12: JDQ443 Phase III (NCT05132075) Study - Initiation & Completion Year
  • Figure 5-13: Divarasib (GDC-6036) Phase I/II (NCT05789082) Study - Initiation & Completion Year
  • Figure 5-14: Japan - Approved Companion Diagnostic Tests Lumakras
  • Figure 5-15: Sotorasib Phase I (NCT05451056) Study - Initiation & Completion Year
  • Figure 5-16: Hanmi Group - HM99462
  • Figure 5-17: DigmBio & Inno Pharma Screen Collaboration
  • Figure 5-18: Canada - Key Universities & Institutes Steering KRAS Clinical Trials
  • Figure 5-19: Anbogen Therapeutics - ABT-202 Insights
  • Figure 5-20: BBP-398 in Combination With Sotorasib Phase I (NCT05480865) Study - Initiation & Completion Year
  • Figure 6-1: D-1553 Phase III (NCT06300177) Study - Initiation & Completion Year
  • Figure 6-2: D-1553/Garsorasib - NMPA Prioritized Evaluation & Breakthrough Designations
  • Figure 6-3: JAB-21822 with JAB-3312 Phase III (NCT06416410) Study - Initiation & Completion Year
  • Figure 6-4: Sotorasib Phase 3 (NCT05198934) Study - Initiation & Completion Year
  • Figure 6-5: Sotorasib Phase 3 (NCT06252649) Study - Initiation & Completion Year
  • Figure 6-6: Adagrasib Phase 1/2 (NCT03785249) Study - Initiation & Completion Year
  • Figure 6-7: Divarasib Phase 1 (NCT04449874) Study - Initiation & Completion Year
  • Figure 6-8: Adagrasib Phase 1 (NCT05634525) Study - Initiation & Completion Year
  • Figure 6-9: Adagrasib Phase 1 (NCT06130254) Study - Initiation & Completion Year
  • Figure 6-10: JAB-21822 Phase 2 (NCT06008288) Study - Initiation & Completion Year
  • Figure 6-11: Anti-KRAS G12V mTCR PBL Phase I/II (NCT03190941) Study - Initiation & Completion Year
  • Figure 7-1: Global - KRAS Protein inhibitors Clinical Trials by Country, 2024 -2030
  • Figure 7-2: Global - KRAS Protein inhibitors Clinical Trials by Phase, 2024 -2030
  • Figure 7-3: Global - KRAS Protein inhibitors Clinical Trials by Company, 2024 -2030
  • Figure 7-4: Global - KRAS Protein inhibitors Clinical Trials by Indication, 2024 -2030
  • Figure 7-5: Global - KRAS Protein inhibitors Clinical Trials by Patient Segment, 2024 -2030
  • Figure 10-1: Combination of KRAS inhibitors with Various Immunotherapeutic Modalities
  • Figure 10-2: RMC-6236 with Bevacizumab Phase I/II (NCT06445062) Study - Initiation & Completion Year
  • Figure 10-3: JDQ443 With Trametinib Phase I/II (NCT05358249) Study - Initiation & Completion Year
  • Figure 10-4: D-1553 With GH21 Phase I/II (NCT06435455) Study - Initiation & Completion Year
  • Figure 11-1: KRAS Inhibitors Market - Drivers & Opportunities
  • Figure 11-2: KRAS Inhibitors Market - Drivers & Opportunities
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!